Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Sep;33(9):1504-1505.
doi: 10.1002/mds.27443. Epub 2018 Aug 25.

Increased substantia nigra echogenicity in LRRK2 family members without mutations

Mariel Pullman  1   2 , Roberto Ortega  2 , Amanda Glickman  2 , Andres Deik  1   3 , Deborah Raymond  2 , Karen Marder  4 , Nir Giladi  5 , Susan Bressman  1   2 , Johann Hagenah  6 , Norbert Brüggemann  7 , Rachel Saunders-Pullman  1   2
Affiliations

Increased substantia nigra echogenicity in LRRK2 family members without mutations

Mariel Pullman et al. Mov Disord. 2018 Sep.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Relevant conflicts of interest/financial disclosures: None of the authors report any financial disclosures or conflicts of interest.

Figures

FIG. 1.
FIG. 1.
Clinical characteristics and echogenicity. NCFs, non-carrier family members; NMCs, non-manifesting G2019S carriers; LRRK2 PD, PD with G2019S LRRK2 mutations; IPD, idiopathic PD; aSNMax, maximum area (right or left side) of substantia nigra hyperechogenicity. All continuous-variable results reported as mean (SD). Superscripts denote significant differences from the superscripted group (P < 0.05) in the linear mixed-effects model. Twenty-eight IPD, 32 LRRK2 PD, 15 NMC, and 40 controls were included in the original study. Three hundred fifteen of the total 325 subjects had sufficient data to be included in the model. *Age at onset, disease duration available for 67 IPD, 55 LRRK2 PD.
See this image and copyright information in PMC

References

    1. Lubbe SJ, Escott-Price V, Gibbs JR, et al. Additional rare variant analysis in Parkinson’s disease cases with and without known pathogenic mutations: evidence for oligogenic inheritance. Hum Mol Genet 2016;25(24):5483–5489. - PMC - PubMed
    1. Klein C, Chuang R, Marras C, Lang AE. The curious case of phenocopies in families with genetic Parkinson’s disease. Mov Disord 2011; 26(10):1793–802. - PubMed
    1. Berg D, Roggendorf W, Schröder U, et al. Echogenicity of the substantia nigra: association with increased iron content and marker for Susceptibility to nigrostriatal injury. Arch Neurol 2002;59(6): 999–1005. - PubMed
    1. Brüggemann N, Hagenah J, Stanley K, et al. Substantia nigra hyperechogenicity with LRRK2 G2019S mutations. Mov Disord 2011; 26(5):885–888. - PMC - PubMed
    1. Sierra M, Sánchez-Juan P, Martínez-Rodríguez MI, et al. Olfaction and imaging biomarkers in premotor LRRK2 G2019S-associated Parkinson disease. Neurology 2013;80(7):621–626. - PubMed

Publication types

Substances